Mark  Sullivan net worth and biography

Mark Sullivan Biography and Net Worth

General Counsel of Sesen Bio
Mark R. Sullivan brings more than 20 years of legal experience to his role as general counsel, chief compliance officer and corporate secretary.  Before joining Sesen Bio in April 2018, he provided outsourced in-house counsel services to companies in the life sciences and healthcare industries, including Sandoz Inc. and Bayer Healthcare. Prior to that, Mr. Sullivan served as the general counsel, chief compliance officer and secretary of MModal Inc., a public healthcare IT company for 9 years, until the company was taken private by One Equity Partners in July 2012.  At MModal, Mr. Sullivan was responsible for all securities, intellectual property, corporate governance, mergers and acquisitions, contracting and risk management matters, and he implemented and managed a formal compliance program for over 14,000 employees.  Prior to MModal, Mr. Sullivan was an attorney at the law firms of Pepper Hamilton LLP and Drinker Biddle & Reath LLP, where his practice focused on corporate and securities matters. Mr. Sullivan holds a J.D. from Rutgers University School of Law and a Bachelor of Arts from the University of Pennsylvania.

What is Mark Sullivan's net worth?

The estimated net worth of Mark Sullivan is at least $0.00 as of March 2nd, 2023. Mr. Sullivan owns 9,935 shares of Sesen Bio stock worth more than $0 as of May 8th. This net worth estimate does not reflect any other investments that Mr. Sullivan may own. Learn More about Mark Sullivan's net worth.

How do I contact Mark Sullivan?

The corporate mailing address for Mr. Sullivan and other Sesen Bio executives is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. Sesen Bio can also be reached via phone at (617) 444-8550 and via email at [email protected]. Learn More on Mark Sullivan's contact information.

Has Mark Sullivan been buying or selling shares of Sesen Bio?

Mark Sullivan has not been actively trading shares of Sesen Bio over the course of the past ninety days. Most recently, Mark Sullivan sold 10,960 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $11.80, for a transaction totalling $129,328.00. Following the completion of the sale, the general counsel now directly owns 9,935 shares of the company's stock, valued at $117,233. Learn More on Mark Sullivan's trading history.

Who are Sesen Bio's active insiders?

Sesen Bio's insider roster includes Thomas Cannell (CEO), Monica Forbes (CFO), Glen Macdonald (CTO), and Mark Sullivan (General Counsel). Learn More on Sesen Bio's active insiders.

Mark Sullivan Insider Trading History at Sesen Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2023Sell10,960$11.80$129,328.009,935View SEC Filing Icon  
2/21/2023Sell1,991$11.80$23,493.8014,984View SEC Filing Icon  
See Full Table

Mark Sullivan Buying and Selling Activity at Sesen Bio

This chart shows Mark Sullivan's buying and selling at Sesen Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sesen Bio Company Overview

Sesen Bio logo
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $10.50
Low: $0.63
High: $12.99

2 Week Range

Now: N/A

Volume

93,330 shs

Average Volume

1,067,298 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83